Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Private placement notes sold to investors under Securities Act Section 4(a)(2), avoiding public registration.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Private placement notes sold to investors under Securities Act Section 4(a)(2), avoiding public registration
- Potential conversion dilution of up to 13,631,400 common shares
- Initial conversion rate of 54.5256 shares per $1,000 principal amount, subject to anti-dilution adjustments
- Unregistered notes and conversion shares carry resale restrictions absent registration or an exemption
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.